Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples